|
|
|
1 Modeling and Informatics in Drug Design (Prasad V. Bharatam, Smriti Khanna, and Sandrea M. Francis). |
|
|
|
2 Computer Techniques: Identifying Similarities Between Small Molecules (Peter Meek, Guillermo Moyna, and Randy Zauhar). |
|
|
|
3 Protein–Protein Interactions (Kamaljit Kaur, Dipankar Das, and Mavanur R. Suresh). |
|
|
|
4 Method Development for Preclinical Bioanalytical Support (Masood Khan and Naidong Weng). |
|
|
|
5 Analytical Chemistry Methods: Developments and Validation (Izet M. Kapetanovic and Alexander V. Lyubimov). |
|
|
|
6 Chemical and Physical Characterizations of Potential New Chemical Entity (Adegoke Adeniji and Adeboye Adejare). |
|
|
|
7 Permeability Assessment (Srinivas Ganta, Puneet Sharma, and Sanjay Garg). |
|
|
|
8 How and Where Are Drugs Absorbed? (Marival Bermejo and Isabel Gonzalez-Alvarez). |
|
|
|
9 Absorption of Drugs after Oral Administration (Luis Granero and Ana Polache). |
|
|
|
10 Distribution: Movement of Drugs through the Body (Jayanth Panyam and Yogesh Patil). |
|
|
|
11 The Blood–Brain Barrier and Its Effect on Absorption and Distribution (A. G. de Boer and P. J. Gaillard). |
|
|
|
12 Transporter Interactions in the ADME Pathway of Drugs (Yan Zhang and Donald W. Miller). |
|
|
|
13 Accumulation of Drugs in Tissues (Krishnamurthy Venkatesan, Deepa Bisht, and Mohammad Owais). |
|
|
|
14 Salt and Cocrystal Form Selection (Ann W. Newman, Scott L. Childs, and Brett A. Cowans). |
|
|
|
15 Dissolution (A.K. Tiwary, Bharti Sapra, and Subheet Jain). |
|
|
|
16 Stability: Physical and Chemical (Eric M. Gorman, Brian E. Padden, and Eric J. Munson). |
|
|
|
17 Dosage Formulation (Alexander V. Lyubimov). |
|
|
|
18 Cytochrome P450 Enzymes (Eugene G. Hrycay and Stelvio M. Bandiera). |
|
|
|
19 Metabolism Kinetics (Charles W. Locuson and Timothy S. Tracy). |
|
|
|
20 Drug Clearance (Sree D. Panuganti and Craig K. Svensson). |
|
|
|
21 In Vitro Metabolism in Preclinical Drug Development (Olavi Pelkonen, Ari Tolonen, Miia Turpeinen, and Jouko Uusitalo). |
|
|
|
22 Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug–Drug Interactions (Jane R. Kenny, Dermot F. McGinnity, Ken Grime, and Robert J. Riley). |
|
|
|
23 In Vivo Metabolism in Preclinical Drug Development (Sevim Rollas). |
|
|
|
24 In Vitro Evaluation of Metabolic Drug–Drug Interactions: Scientific Concepts and Practical Considerations (Albert P. Li). |
|
|
|
25 Mechanisms and Consequences of Drug–Drug Interactions (Dora Farkas, Richard I. Shader, Lisa L. von Moltke, and David J. Greenblatt). |
|
|
|
26 Species Comparison of Metabolism in Microsomes and Hepatocytes (Niels Krebsfaenger). |
|
|
|
27 Metabolite Profi ling and Structural Identifi cation (Mehran F. Moghaddam). |
|
|
|
28 Linkage between Toxicology of Drugs and Metabolism (Ruiwen Zhang and Elizabeth R. Rayburn). |
|
|
|
29 Allometric Scaling (William L. Hayton and Teh-Min Hu). |
|
|
|
30 Interrelationship between Pharmacokinetics and Metabolism (James W. Paxton). |
|
|
|
31 Experimental Design Considerations in Pharmacokinetic Studies (William W. Hope, Vidmantas Petraitis, and Thomas J. Walsh). |
|
|
|
32 Bioavailability and Bioequivalence Studies (Alexander V. Lyubimov and Ihor Bekersky). |
|
|
|
33 Mass Balance Studies (Jan H. Beumer, Julie L. Eiseman, and Merrill J. Egorin). |
|
|
|
34 Pharmacodynamics (Beom Soo Shin, Dhaval Shah, and Joseph P. Balthasar). |
|
|
|
35 Physiologically Based Pharmacokinetic Modeling (Harvey J. Clewell III, Micaela B. Reddy, Thierry Lave, and Melvin E. Andersen). |
|
|
|
36 Mathematical Modeling as a New Approach for Improving the Effi cacy/Toxicity Profi le of Drugs: The Thrombocytopenia Case Study (Zvia Agur, Moran Elishmereni, Yuri Kogan, Yuri Kheifetz, Irit Ziv, Meir Shoham, and Vladimir Vainstein). |
|
|
|
37 Regulatory Requirements for INDs/FIH (First in Human) Studies (Shayne Cox Gad). |
|
|
|
38 Data Analysis (Jayesh Vora and Pankaj B. Desai). |
|
|
|
|